

PROGRAMMA FAD

Ricerca clinica e innovazione sanitaria: strumenti, responsabilità e nuovi modelli operativi

_Modulo 1 – La ricerca clinica e il ruolo del medico: contesto, finalità e attori

- La centralità della ricerca clinica profit/no profit
- Il ruolo dell'investigatore e la filiera dei soggetti coinvolti (sponsor, CRO, CE, autorità regolatorie)
- L'importanza del PI nella qualità scientifica e nella compliance etica e normativa

_Modulo 2 – Tipologie e disegni degli studi clinici: scegliere, condurre, interpretare

- Studi interventistici vs osservazionali: caratteristiche e obiettivi
- Studi prospettici e retrospettivi: criteri di applicazione
- Studi real-world evidence (RWE): nuove prospettive per il medico pratico
- Cenni ai disegni adattivi e bayesiani

_Modulo 3 – Etica, normativa e responsabilità: lo studio clinico tra scienza e tutela del paziente

- Normativa internazionale (ICH-GCP, dichiarazione di Helsinki) e nazionale
- Il consenso informato e i diritti del soggetto
- Privacy, trasparenza, accesso ai dati e uso secondario dei dati sanitari
- Le responsabilità legali e deontologiche del medico investigatore

_Modulo 4 – Progettare uno studio clinico: dalla teoria alla pratica

- Domanda di ricerca, ipotesi clinica e identificazione dell'endpoint
- Disegno sperimentale, arruolamento e gestione del campione
- Criteri di inclusione/esclusione, gestione del bias
- La gestione del protocollo: CRF, SAE, auditing

Modulo 5 – Ricerca clinica 4.0: innovazione digitale, decentralizzazione e trial ibridi

- L'evoluzione tecnologica: eConsent, ePRO, piattaforme digitali
- Nuovi modelli organizzativi: trial decentralizzati e home-based
- La sfida dei Big Data e dell'intelligenza artificiale nella sperimentazione clinica
- Integrazione con i database sanitari nazionali e regionali



Evidilya s.r.l.

CURRICULUM VITAE

EMPLOYEE INFORMATION

Full name	Cesare Mutti
Sprim location	Evidilya s.r.l. Via Brisa 3, 20123 Milano
Job Title	Business Unit Director
Business Title	BU Director
Supervisor Name	Emmanuel Pauze
Country of residence	Italy
Regular/Temp. Status	Regular

Evidilya EXPERIENCE

Jan 2018-curent	Business Unit Director
	<ul style="list-style-type: none"> • Coordination of European Business Development activities of research and clinical services in the field of Food, Functional Food, Food Ingredients, Medical Device, OTC, Pharma, Cosmetics • Implementation of New Business and Existing Business Consolidation at EMEAR and Global level • New Business identification and new scientific insights translation into business opportunities • Development of Proposals and Budgets • Global Oversight on Business Unit for Project Tracking, Projects Financial Management
	BU Direction

Feb 2012-Jan 2018	Business Development Manager
	<ul style="list-style-type: none"> • Coordination of European Business Development activities of research and clinical services in the field of Food, Functional Food, Food Ingredients, Medical Device, OTC, Pharma, Cosmetics • Implementation of New Business and Existing Business Consolidation In Italy, Spain and Northern Europe • New Business identification and new scientific insights translation into business opportunities • Development of Proposals and Budgets • Sponsor and Supply Chain Budgets negotiation



Evidilya s.r.l.

CURRICULUM VITAE

	<ul style="list-style-type: none"> • Design and Implementation of Company's promotional Toolkits (leaflet, Brochures, Presentations) • Coordination of local operational activities (monitoring visits, data flow from sites / central)
	Business Development

ADDITIONAL WORK EXPERIENCE

	<p>R&D Specialist Prof. Elena Cattaneo "Laboratory of stem cells biology and pharmacology of neurodegenerative diseases" Department of Pharmacological Sciences and Centre for Stem Cells Research Via Viotti 3/5, 20133 Milano University of Milano www.cattaneolab.it</p>
March 2009-Feb 2012	<ul style="list-style-type: none"> • Internship of Responsible of Disease Modelling Group and Compound Selection and Screening • Development and characterization of novel neural stem cell systems carrying pathological features of Huntington's Disease • Identification and screening of novel chemical compounds useful for therapeutic approaches in Huntington's Disease • Business Development related to new stem cell base in vitro models and in-out licensing business opportunities related to new pharmaceutical compounds in Neurodegenerative Disorders
	R&D



Evidilya s.r.l.

CURRICULUM VITAE

Feb 2006 -March 2009	Prof. Elena Cattaneo, Dr.ssa Dorotea Rigamonti Dialectica s.r.l. c/o Nerviano Medical Sciences Viale Pasteur 10, 20014 Nerviano (MI) www.nms.com
	<ul style="list-style-type: none"> • Development and characterization of novel neural stem cell systems carrying pathological features of neurodegenerative diseases • Derivation and characterization of electrophysiological and pharmacological active neural stem cells derived neurons • Identification and screening of novel chemical compounds active for neurodegenerative diseases.
	R&D

EDUCATION

1995-2000	High School Diploma
	Istituto Statale d'Istruzione superiore "Francesco Gonzaga"
	Via F.lli Lodrini, 46043 Castiglione delle Stiviere (MN)
	ISCED 3

TRAINING

Nov 2019	Leadership e Gestione dello Stress
	Athena S.p.a.
Nov 2018	Problem Solving and Decision Making
	R.T.S Srl



Evidilya s.r.l.

CURRICULUM VITAE

PERSONAL SKILLS

Mother tongue(s)	Italian				
Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
ENGLISH	C2	C2	C1	C1	C1
	Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user Common European Framework of Reference for Languages				

Organisational / managerial skills	<p>Great skills in team-working and ability in interactions. Great capabilities in diplomacy and proficient skills in Management Good command in the field of problem solving and great skills in analysis and team coordination. Pro-activity and focused on process streamlining.</p> <ul style="list-style-type: none"> leadership (currently responsible for a team of 3 people) + oversight on Business Unit management of CRO (currently managing team of 10 people)
------------------------------------	---

Job-related skills	<p>Good Command and knowledge in the filed of Clinical Trials and RWE studies regulation EMA/FDA and EFSA Guidelines. Italian legislative decrees about clinical research / GCP (DM 15/11/2011) European regulation about health claims made on food: EC Regulation 1924/2006 EC Regulation 353/2008 EFSA guidelines for food, food ingredients, botanicals, food integrators MDR 745/2017 and MEDDEV Guidelines on Medical Devices EU 1223/2009 Cosmetics Regulation</p>
--------------------	---

Digital competence	SELF-ASSESSMENT				
	Information processing	Communication	Content creation	Safety	Problem solving
	Independent User	Independent User	Independent User	Independent User	Independent User
	Levels: Basic user - Independent user - Proficient user Digital competences - Self-assessment grid				
	Replace with your other computer skills. Specify in what context they were acquired. Example: Good Command in the use of Microsoft applications and Microsoft Office package (Word, Excel,				



Evidilya s.r.l.

CURRICULUM VITAE

	PowerPoint, Outlook, Teams) as well as CRM softwares (Microsoft Dynamics) Competent in using iOS Mac Operative System Competent in using PubMed Competent in the use of chemical drawing softwares (ChemDraw, Chem3D, MarvinSpace, MarvinSketch).
--	--

Other skills	Good command in marketing tools and strategies acquired during Business Development activities and networking with worldwide customers.
--------------	---

Driving licence	Driving Licence "B"
-----------------	---------------------

ADDITIONAL INFORMATION

Publications Presentations Projects Conferences Seminars Honours and awards Memberships References Citations Courses Certifications	<p>February 2006-December 2009 Member of the European Project "STEM-HD, stem cells and therapeutics and exploration of mechanism in Huntington's Disease" Specific Targeted Research Project, FP6 Programme (EU) www.stemhd.eu</p> <p>PUBLICATIONS:</p> <ul style="list-style-type: none"> • Conforti P, Zuccato C, Gaudenzi G, Ieraci A, Camnasio S, Buckley NJ, Mutti C, Cotelli F, Contini A, Cattaneo E. <i>J Neurochem.</i> 2013 Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models. • Conforti P, Camnasio S, Mutti C, Valenza M, Thompson M, Fossale E, Zeitlin S, MacDonald ME, Zuccato C, Cattaneo E. <i>Neurobiol Dis.</i> 2013 • Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. • Diaferia GR., Conti L., Redaelli S., Cattaneo M., Mutti C., De Blasio P., Dalprà L., Cattaneo E., Biunno I. <i>Stem Cells Dev.</i> 2011 Systematic chromosomal analyses of cultured mouse neural stem cell lines • Rigamonti D., Mutti C., Zuccato C., Cattaneo E., Contini A. <i>Curr Pharm Des.</i> 2009 Turning REST/NRSF dysfunction in Huntington's Disease into a pharmaceutical target • Leone S., Mutti C., Kazantsev A., Sturlese M., Moro S., Cattaneo E., Rigamonti D., Contini A. <i>Bioorg Med Chem.</i> 2008 SAR and QSAR study of 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's Disease • Rigamonti D., Bolognini D., Mutti C., Zuccato C., Tartari M., Sola F., Valenza M., Kazantsev AG., Cattaneo E. <i>J Biol Chem.</i> 2007
---	--




Evidilya s.r.l.

CURRICULUM VITAE

	Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators

	▪ N/A
--	-------

Data 18/12/2024

Firma
DocuSigned by:

BBD40A1ABD6A4DA...

CURRICULUM VITAE

[choose the correct logo among those above]

EMPLOYEE INFORMATION

Full name	GIANLUCA CILIBERTO
Sprim location	Milan
Job Title	Lead Clinical Project Manager
Business Title	Lead Clinical Project Manager
Supervisor Name	Cesare Mutti
Country of residence	Italy
Regular/Temp. Status	Regular

SPRIM EXPERIENCE [Add separate entries for each experience. Start from the most recent.]

Gen 2025 -	Lead Clinical Project Manager
	<p>Leading Clinical Operation Team directly reporting to Business Unit Director</p> <ul style="list-style-type: none"> • Provide operational oversight of project status and coordinating studies pipeline advancement and timelines control. • Provide strategical operational insight or operational business unit growth. • Point of contact between the CRO and the Sponsor (e.g. updates about study progress, recruitment, possible issues) • Proactively manage operational aspects including management of trial timelines, internal resources (MW, DM, CRAs, CTAs) and vendors • Provide efficient updates on trial progress to the CLM and HoB with respect to vendor selection, project plans and timeline management • Lead study start up process (submission to the Ethics Committee and regulatory practices), including site selection and site activation (Site Initiation Visit), the set-up of trial master file (TMF) and the finalization of site and vendor Clinical Trial Agreements and budgets • Ensure effective project plans are in place and operational for each trial and work proactively with the Clinical Trial Team to set priorities in accordance with applicable project plans, company standard operational procedures (SOPs), GCP guidelines and regulatory requirements • Ensure all study documentation is filed in the TMF/TCF in accordance with company SOPs/regulatory requirements and provide oversight to the clinical team regarding TMF/TCF filing, maintenance and archival procedures • Effectively provide support to Clinical Research Associate in the conduct of the trial • Review and approve monitoring reports; ensure tracking, follow up and resolution of site issues have been completed in a timely manner • Address quality issues to the appropriate team member(s)
Dec 2023 – Dec 2024	Clinical Project Manager

GIANLUCA CILIBERTO

CURRICULUM VITAE

[choose the correct logo among those above]

	<ul style="list-style-type: none"> - Manage all the clinical trial/RWE study activities and the, organizing the operative tasks evaluating timeframes, according to priorities, and coordinating the dedicated team (MW, DM, CRA, CTA) - Act as a contact point between the CRO and sponsors (ex: updates, potential issues, etc.) - Lead the start-up of the study, including regulatory submissions and approval, handling the recruitment and the on-boarding of the site. - Draw-up and manage Trial Master File (TMF) and Trial Center Files (TCFs) - Share regular updates with the BU Director/Clinical Operation leader on the study status (vendors, activities, timeline and project plan) - Ensure the compliance of TMF/TCF with SOPs, GCP and applicable regulations, overseeing and guiding the clinical team on the suitable policy of TMF and TCF storage and maintenance. - Support the Clinical Research Organization on the monitoring of the trials - Review and approve the monitoring reports, ensuring a quick resolution of potential issues. - Manage the budget and the cost analytics of the project.
	Clinical Research

ADDITIONAL WORK EXPERIENCE [Add separate entries for each experience. Start from the most recent.]

	Clinical Research Coordinator
	IQVIA
Nov 2022 – Dec 2023	<p>On-site CRC activities sponsor dedicated (Genmab) managing 5 research protocols focused on onco-haematology and lymphomas malignancies, from phase I to phase III:</p> <ul style="list-style-type: none"> - Monitor site compliance with trials' protocol and GCP under the direction and delegation of the PI from SIV to COV - Provide constant monitoring support on-site, assist senior CRAs site monitoring activities and SDVs - Safeguard the well-being of subjects and address subject's concerns; ensure subjects education and obtainment of ICF - Maintain studies' staff up-to-date on trial's protocols, eCRFs (Medidata RAVE; Veeva) completion in according to the CRF Guidelines - Participate to Investigator's Meetingsto built and maintain solid communication with trials players - Management of vendor's CTMSs in a timely fashion and of study documents utilizing available reports and study tools - Review research specimen sample documentation, storage and processing, and ensure shipments are sent to central lab as required - Perform data entry/query resolution meeting deadlines and sponsor's interim analysis; upkeep regulatory/trial binders audit-proof - Report protocol variations, issue resolution, and follow-up compliance and quality control of data in compliance with ALCOA-CCEA

GIANLUCA CILIBERTO

CURRICULUM VITAE

[choose the correct logo among those above]

	<ul style="list-style-type: none"> - Work proactively with sites to address discrepancies and action items to obtain swift resolution and escalate to PL/PI per CMP
	Therapeutic area and main topics: Lymphomas (DLBCL; FL; HSCT, ML)
	Clinical Research

	Research Assistant and Project Manager
	Ospedale San Raffaele · Full-time
Feb 2022 – Nov 2022	<p>Project Manager and Coordinator at the Immunogenetics, Leukemia Genomics and Immunobiology Unit directed by Prof. Luca Vago. Management of multiple preclinical projects focused on modern immunotherapies to fight solid and liquid tumors.</p> <ul style="list-style-type: none"> - Strong knowledge on modern available treatment to fight oncology diseases based on ATMPs (BsAbs; CAR-T; Checkpoint Inhibitors; LV-based Gene Therapy) from wet lab to preclinical tests - Design, implementation and oversight of experimental action plans till high-degree presentations for scientific insights sharing - Interaction with academic and pharma KOLs interested in engaging scientific discussion and establishing close working relationships - Provide support and mentoring to preclinical team with training of new hires through aggressive scientific education - Responsible for financial management and requested resources for assigned projects <p>Therapeutic area and main topics: Cancer immunology; Haematology; TMO; Cell Therapy; Gene Therapy.</p>

	CTE/Project Coordinator
	ClinOpsHub
Jul 2022 – Oct 2022	<p>Remote activities as Clinical Educator/Project Coordinator for the development of tailored strategies based on SWOT analysis of protocol and clinical sites to assess KOLs networks countrywide:</p> <ul style="list-style-type: none"> - Enhance patient recruitment and education by contacting investigators as specified for the study - Assist in identifying and qualifying potential investigators; Facilitate site selection to speed up the ready-to-enroll status - Deepen the Patient Pathway to uncover referral opportunities; Drafting PowerPoint presentations on clients' scientific topics - Provide scientific background according to communication strategy

GIANLUCA CILIBERTO

CURRICULUM VITAE

[choose the correct logo among those above]

	Therapeutic area and main topics: Lymphomas; Myelofibrosis.
Jul 2020 – Jan 2022	<p>Research Assistant Intern</p> <p>Libera Università Vita-Salute San Raffaele</p> <p>Research Intern for MSc thesis: CRISPR/Cas9-based genome editing to model the anti-leukemia immune response and identify its molecular players. Supervisor Prof. Fabio Ciceri.</p> <ul style="list-style-type: none"> - Project and team leader of a 3-year funded project focused on post HSCT-immune resistance events in relapsed from AML - High-throughput technology of genome editing and genome-wide CRISPR/Cas9 screenings to unveil tumor immune-modulators <p>Therapeutic area and main topics: Onco-haematology; Immune therapy; Cell and Gene Therapy; HSCT</p>
Nov 2018 – Feb 2019	<p>Laboratory Research Assistant</p> <p>University of Plymouth, Peninsula Medical School, Plymouth (UK)</p> <p>Visiting Scholar in Mitochondria Biology Unit directed by Prof. Charles Affourtit.</p> <ul style="list-style-type: none"> - I took part in the LUMIBLST Project, a 5-year project funded by the European Union's Horizon 2020 framework - Purpose was to establish novel non-invasive extra-cellular systems for Glioblastoma Multiforme (GBM) treatment - Technology combination of Photo Dynamic Therapy (PDT) with a chemiluminescent chemical - I have been involved directly in proof-of-principle wet lab experiments guided by Knight Scientific Ltd. <p>Therapeutic area and main topics: Glioblastoma; Cell Therapy; Conjugated chemicals</p>
Oct 2018 – Feb 2019	<p>Project Coordinator</p> <p>Knight Scientific Ltd</p> <p>Visiting scholar Erasmus for Traineeship at KSL as Project Coordinator</p> <ul style="list-style-type: none"> - Strong knowledge in the diagnostic field of oxidative stress response and chemiluminescent chemicals - Involved in standardization and QC of pharmaceutical manufacturing in compliance with company SOP and QC

GIANLUCA CILIBERTO

CURRICULUM VITAE

[choose the correct logo among those above]

	- Data Monitoring; eCRF Management; Query solving and Source Data Review in compliance with ALCOA-CCEA. Therapeutic area and main topics: Data Management; QC; Oxidative stress response; pharmaceuticals manufacturing
--	--

Apr 2018 – Feb 2019	Laboratory Research Assistant
	University of Eastern Piedmont
	Research Internship in Wound Healing Lab, Human Anatomy Unit directed by Prof. Filippo Renò
	Thesis title: Effect of PLT-MV on human keratinocytes in an in vitro wound-healing model. Human keratinocytes were evaluated to be susceptible to stimuli coming from platelet microvesicles content, as circRNA encoding for growth factors. Therapeutic area and main topics: Wound Healing; Diabetes; Cardiovascular diseases; Haematology; Cell Therapy.

EDUCATION (Add separate entries for each relevant course you have completed, starting from the most recent (To delate in final version))

Oct 2019 – Feb 2023	Master's degree in Biotechnology and Medical Biology
	Libera Università Vita-Salute San Raffaele, Milan

2015- 2019	Bachelor's degree in Biotechnology
	Università degli Studi del Piemonte Orientale, Novara

TRAINING (Add separate entries for each relevant course you have completed, starting from the most recent (To delate in final version))

Replace with date	Clinical Research training course "Missione CRA"
	ClinOpsHub; Yghea CRO

PERSONAL SKILLS

GIANLUCA CILIBERTO

CURRICULUM VITAE

[choose the correct logo among those above]

Mother tongue(s)	Italian				
Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1/C2	C1/C2	C1/C2	C1/C2	C1/C2
	LanguageCert Test of English C1				
Replace with language	Enter level	Enter level	Enter level	Enter level	Enter level
	Replace with name of language certificate. Enter level if known.				
	Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user Common European Framework of Reference for Languages				

Organisational / managerial skills	<ul style="list-style-type: none"> - Excellent organizational skills acquired throughout almost 5 years of research laboratory working and 2 years of clinical sites management. - Leadership acquired through project and research group leading
------------------------------------	---

Job-related skills	<ul style="list-style-type: none"> - Capable of working in both individual and team contexts - Effusive and capable of maintain effective working relationships with coworkers, managers, and KOLs - Able to speed up team working, idea and decision making - Proactive and self-motivating with effective time and financial management skills - Updated through seminars participation, literature and web searching - Skilled in public speaking due to oral presentations, journal clubs and team meetings for data presentation - Good temperance and management of stressful situations - Quite competitive and easily adapting to novel challenges
--------------------	--

Digital competence	SELF-ASSESSMENT				
	Information processing	Communication	Content creation	Safety	Problem solving
	Proficient user	Proficient user	Proficient user	Proficient user	Proficient user
	Levels: Basic user - Independent user - Proficient user				
	Digital competences - Self-assessment grid				
	Replace with name of ICT-certificate(s)				
<ul style="list-style-type: none"> - Advanced user of eCRF (Medidata, REDCap). - Advanced user of MS Office (Word, Excel, Outlook, PowerPoint, OneNote, Access). - Good ability in shareable datasheet, Clouds (Drive, Dropbox). - Forward skills in searching for scientific publications, biomedical literature browser (PubMed, ClinicalTrials.gov). - Basic knowledge with bioinformatic software (SAS; RStudio) and programming language. 					

Other skills	None
--------------	------

Driving licence	B
-----------------	---

GIANLUCA CILIBERTO

CURRICULUM VITAE

[choose the correct logo among those above]

ADDITIONAL INFORMATION

Publications	<p>Milan Meets Immunology 2022: Abstract selected for Poster Presentation (Milano, 8th June 2022)</p> <p>- XVII SIES National Congress: Abstract selected for Oral Presentation (Roma, 31st March-2nd April 2022). Best abstract awarded (Haematologica, April 2022)</p> <p>- San Raffaele Retreat 2022: Abstract selected for Poster Presentation (Baveno, 10th March-11th March 2022)</p> <p>- San Raffaele DITID 2022: Abstract selected for Oral Presentation (Milano, 12th January-13th January 2022)</p> <p>- SIES member: Member of the Società Italiana di Ematologia Sperimentale (SIES)</p> <p>-GCP for Investigational Studies Training: December 2022 by IQVIA</p>
Presentations	
Projects	
Conferences	
Seminars	
Honours and awards	
Memberships	
References	
Citations	
Courses	
Certifications	

ANNEXES

	▪ None
--	--------

Date.....03/02/2025.....

Signature.....



Curriculum Vitae Europass

Informazioni personali

Cognome(i)/Nome(i) **MOSCONI PAOLA**
Indirizzo(i) Via Lorenzo Mascheroni, 29 – 20145 Milano - Italia
Telefono(i) 3355607346
Fax
E-mail moscogale@gmail.com
Cittadinanza Italiana
Luogo e data di nascita Milano, 25 Luglio 1957
Codice Fiscale MSCPLA57L65F205W
Sesso Femminile

**Occupazione
desiderata/Settore
professionale** Consulente

Esperienza professionale

Date	2005-2024	Capo Laboratorio di ricerca sul coinvolgimento dei cittadini in sanità, Dipartimento di Salute Pubblica
	1996-2005	Capo Unità per la Valutazione del Ruolo del Paziente nella Assistenza Sanitaria, già Unità di Outcome Research
	dal 1997	Ricercatore Laboratorio Ricerca Clinica Oncologica e Traslazionale
	dal 95 al 97	Ricercatore Laboratorio di Epidemiologia della Assistenza Sanitaria
	dal 88 al 95	Ricercatore Laboratorio di Epidemiologia Clinica
	dal 82 al 88	Ricercatore Istituto di Ricerche Farmacologiche "Mario Negri" Laboratorio di Farmacologia Clinica
	1980-1981	Tesista - Istituto di Ricerche Farmacologiche "Mario Negri"
Lavoro o posizione ricoperti	Ricercatore con qualifica di Capo Laboratorio	
Principali attività e responsabilità	Pianificazione, coordinamento, analisi dei risultati, presentazione e divulgazione di progetti di ricerca mirati alle aree di interesse	
Nome e indirizzo del datore di lavoro	Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2 - 20156 Milano	
Tipo di attività o settore	Fondazione no-profit	
Date	1990-2000	Assunto dalla Regione Lombardia con la qualifica di Ricercatore distaccato funzionalmente presso l'Istituto "Mario Negri"
Lavoro o posizione ricoperti	Ricercatore I° Livello quadro distaccato funzionalmente presso l'Istituto Mario Negri,	

Principali attività e responsabilità	Pianificazione, coordinamento, analisi dei risultati, presentazione e divulgazione di progetti di ricerca mirati alle aree di interesse
Nome e indirizzo del datore di lavoro	Regione Lombardia Via Pola 12/14 – 20124 Milano
Tipo di attività o settore	Ente Istituzionale Pubblico
Istruzione e formazione	
Date	1989
Titolo della qualifica rilasciata	Iscrizione Ordine Nazionale dei Biologi (numero 032931)
Principali tematiche/competenza professionali possedute	
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Ordine Nazionale Biologi Via Icilio, 7 – 00153 Roma
Livello nella classificazione nazionale o internazionale	Facoltativo (v. istruzioni)
Date	1988
Titolo della qualifica rilasciata	
Principali tematiche/competenza professionali possedute	Periodo di studio e formazione
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Department of Psychology, Vanderbilt University, Nashville, USA Prof. Beth E. Meyerowitz
Livello nella classificazione nazionale o internazionale	
Date	1984
Titolo della qualifica rilasciata	Specialista in Ricerca Farmacologica
Principali tematiche/competenza professionali possedute	
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Regione Lombardia - Istituto di Ricerche Farmacologiche "Mario Negri"
Livello nella classificazione nazionale o internazionale	
Date	1982
Titolo della qualifica rilasciata	Laurea in Scienze Biologiche, Indirizzo Sanitario
Principali tematiche/competenza professionali possedute	
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Milano
Livello nella classificazione nazionale o internazionale	

Capacità e competenze personali

Madrelingua **Italiano**

Altra(e) lingua(e)

Autovalutazione

Livello europeo (*)

Inglese


Francese

Comprensione		Parlato		Scritto	
Ascolto	Lettura	Interazione orale	Produzione orale		
Buono	Buono	Buono	Buono	Buono	
Buono	Buono	Scolastico	Scolastico	Scolastico	

Capacità e competenze	<p>Esperienze di studio e di lavoro, anche all'estero, di carattere multidisciplinari e multiculturale. Ricercatore dapprima nei settori della Farmacologia Clinica e della Epidemiologia Clinica, è coinvolta dal 1987 in progetti sulla partecipazione attiva dei cittadini e pazienti nel dibattito sulla salute, sulla informazione e formazione e in progetti di ricerca e partnership con associazioni di volontariato.</p> <p>Principali aree di interesse:</p> <ul style="list-style-type: none"> • metodologia della ricerca: conferenze di consenso, giurie dei cittadini, linee guida, indagini ad hoc con associazioni, indagini su conoscenze/ atteggiamenti/comportamenti di cittadini/pazienti, registri di patologia, revisioni • informazione: valutazione del tipo di informazione fornita e da fornire su screening, malattie e trattamenti; modalità di comunicazione di informazioni di salute anche attraverso lo sviluppo di siti internet come www.partecipasalute.it, www.fondazionemattioli.it, www.ecranproject.eu, http://indeep.istituto-besta.it/; sviluppo strumenti decisionali; sviluppo di opuscoli divulgativi per la popolazione generale; • formazione: corsi di metodologia della ricerca clinica per attivisti di associazioni di volontariato; • progetti su valutazione di qualità della vita e salute e soddisfazione del Servizio Sanitario Nazionale sia attraverso studi ad hoc, sia attraverso la messa a punto di questionari <p>Paola Mosconi è stata responsabile di unità operative in programmi di ricerca finalizzati da CNR, Unione Europea e di progetti sostenuti e finanziati da AIRC, Compagnia di San Paolo, Fondazione Luvi, Fondazione Smith Kline, Fondazione Frontier Science & Technology Research Foundation, Fondazione Ricerca Fibrosi Cistica, Fondazione Italiana Sclerosi Multipla, Regione Toscana, Istituto Superiore di Sanità, Agenas, e Aziende ospedaliere.</p> <p>Paola Mosconi ha partecipato in qualità di docente, o coordinatore, alla realizzazione di corsi di formazione professionale e aggiornamento per personale sanitario e rappresentanti di associazioni sui temi della metodologia della ricerca clinica, informazione, metodologia degli studi valutativi in generale e con particolare riferimento ai temi della qualità della vita. Numerose le partecipazioni a congressi nazionali e internazionali.</p> <p>Dal 2006 al 2009 è stata componente del Comitato Etico dell'IRCCS MultiMedica, dal 2007 al 2013 è stata presidente del Comitato Etico dell'Azienda USL di Bologna, nel 2013 del Comitato Etico Provinciale di Reggio Emilia.</p> <p>Fa parte, fin dall'inizio, del Gruppo di Regia del progetto Fare di più non significa fare meglio di Slow Medicine. Insieme a Altroconsumo, ha coordinato l'indagine con cittadini e associazioni <i>"Esami, farmaci e prescrizioni... dite la vostra!"</i>, ha coordinato la messa a punto di materiale informativo – ad esempio le domande da porre al medico, e collabora a tutte le iniziative di coinvolgimento diretto di cittadini, pazienti e loro rappresentanze.</p>
Capacità e competenze organizzative	L'attività di ricerca comporta vari aspetti relativi alla organizzazione e coordinamento di attività tra persone di competenze e con competenze differenti. Anche gli aspetti gestionali del personale e amministrativi sono contemplati nella attività svolta.
Capacità e competenze tecniche	Programmi di scrittura, presentazione, calcolo e analisi statistica
Capacità e competenze informatiche	Descrivere tali competenze e indicare dove sono state acquisite. (facoltativo, v. istruzioni)
Capacità e competenze artistiche	Descrivere tali competenze e indicare dove sono state acquisite. (facoltativo, v. istruzioni)
Altre capacità e competenze	Descrivere tali competenze e indicare dove sono state acquisite. (facoltativo, v. istruzioni)
Patente	Automobile tipo B

La sottoscritta è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000 le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Dichiaro di essere informato ai sensi e per gli effetti dell'art. 13 del D. lgs 196/2003, che il presente curriculum pubblicato nella banca dati presente nel sito <http://ecm.agenas.it> e a tal fine presto il consenso al trattamento dei dati personali contenuti.

La sottoscritta autorizza al trattamento dei dati personali contenuti nel curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 GDPR 679/16



Milano, 05 Settembre 2025

<http://orcid.org/0000-0003-0415-3744>

PUBBLICAZIONI SU RIVISTE PEER REVIEW
 Selezionate da un totale di 160 articoli, abstract esclusi

- Lepore V, Paletta P, Bosetti C, Santucci C, Ponzio M, Pupillo E, Leone M A, Bergamaschi R, Mosconi P, Italian Multiple Sclerosis and Related Disorders Register Centers Group, Scientific Committee of the Italian Multiple Sclerosis and Related Disorders Register. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register. *Mult Scler Relat Disord* 2024; 87: 105638 doi.org/10.1016/j.msard.2024.105638
- Mosconi, P., Colombo, C., Paletta, P. *et al.* Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project. *BMC Cancer* **23**, 814 (2023). <https://doi.org/10.1186/s12885-023-11262-x>
- Mosconi P, Roberto A, Cerana N, Colombo N, Didier F, D'Incalci M, Lorusso D, Peccatori F, Network of Clinicians and Participants. Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of ACTO study. *J Ovarian Res* 2022; 15:45
- Lepore V, Bosetti Cr, Santucci C, Iaffaldano P, Trojano M, Mosconi P. Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *European Journal of Neurology* 2021; 28 (2): 567-578 <https://doi.org/10.1111/ene.14589>
- Roberto A, Colombo Cinzia, Candiani G, Satolli R, Giordano L, Jaramillo L, Castagno R, Mantellini P, Falini P, Carnesciali E, Valenza M, Costa L, Campari C, Caroli S, Faggiano R C, Orione L, Belmessieri B, Marchi AV, Deandrea S, Silvestri A, Luciano D, Paci E, Mosconi P. A dynamic web-based decision aid to improve informed choice in breast cancer organised screening. A pragmatic randomized trial in Italy. *Br J Cancer* 123, 714–721 (2020).
- Mosconi P, Radrezza S, Lettieri E, Santoro E. Use of health apps and wearable devices: survey among Italian associations for patient advocacy. *JMIR mHealth and uHealth* 2019; 7: e10242
- Roberto A, Radrezza S, Mosconi P. Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google Scholar. *Journal of Ovarian Research* 2018;11: 28. DOI: 10.1186/s13048-018-0404-1.
- Castle JC, Chalmers I, Atkinson P, Atkinson P, Badenoch D, Oxman AD, Austvoll-Dahlgren A, Nordheim L, Krause K, Schwartz LM, Woloshin S, Burls A, Mosconi P, Hoffman T, Cusack L, Albarqouni L, Glasziou P. Establishing a library of resources to help people understand key concepts in assessing treatment claims - The “Critical thinking and Appraisal Resource Library (CARL)”. *PLoS ONE* 2017;12(7):e0178666.
- Mosconi P, Colombo C, Satolli R, Carzaniga S. Involving a citizens’ jury in decisions on individual screening for prostate cancer. *PLOS One* 2016; 11: e0143176.
- Mosconi P, Antes G, Barbareschi G, Burls A, Demotes-Mainard J, Chalmers I, Colombo C, Garattini S, et al. A European multi-language initiative to make the general population aware of independent clinical research: The European Communication on Research Awareness Need project. *Trials* 2016; 17:19.
- Mosconi P, Castellani C, Villani W, Satolli R. Cystic fibrosis: to screen or not to screen? Involving a Citizens’ jury in decisions on screening carrier. *Health Expectations* 2015; 8: 1956.
- Donati S, Satolli R, Colombo C, Senatore S, Cotichini R, Da Cas R, Spila Alegiani S, Mosconi P. Informing women on menopause and hormone therapy: *Know the menopause* a multidisciplinary project involving local healthcare system. *PLOS One* 2013; 8 (12).
- Colombo C, Moja L, Gonzalez-Lorenzo M, Liberati A, Mosconi P. Patient empowerment as a component of health system reforms: rights, benefits and vested interests. *Internal and Emergency Medicine* 2012; 7: 183.
- Mosconi P, Colombo C, Satolli R, Liberati A. PartecipaSalute, an Italian project to involve lay people, patients’ associations and scientific-medical representatives on the health debate. *Health Expectations* 2007; 10: 194.
- Mosconi P, Buchanan M, Kyriakides S, Fernandez-Marcos A, Horvatin J, O’Connell D, Zernik N, EUROPA DONNA. EUROPA DONNA: has strenght in its heterogeneity. *European Journal of Cancer* 2004; 40: 1145.
- Apolone G, Mosconi P. The Italian SF-36 Health Survey: Translation, validation and norming. *Journal of Clinical Epidemiology* 1998; 51: 1025.

SITI INTERNET, VIDEO, STRUMENTI DECISIONALI SVILUPPATI:

www.ecranproject.eu, <http://indeep.istituto-besta.it/>, www.fondazionemattioli.it, www.donnainformata-mammografia.it, <https://dart.datariverweb.com/iEnter/?lang=it>

Marta Colaneri, MD

- ◆ **Curriculum vitae**
- ◆ **List of Publications**

Apr 2025



SUMMARY

- Date of birth: 01/02/1992
- **Infectious Diseases specialist**, certified by National Board since 21/12/2021 (mark 70/70, *magna cum laude*)
- **Master's Degree in Medicine and Surgery**, 27/07/2016 (mark 100/100, *magna cum laude*)
- **Extensive experience in clinical research**, testified by the **publication of several articles on international journals, oral communications, and abstract presentation at national and international congresses.**
- **Scopus indexes on 27/09/2022:**
 - **H-index= 21**
 - **Number of articles = (26 as a first author)**
 - **Number of citations = 3,165**
- Editorial experience as a **reviewer** for renowned international journals (**Scientific reports, BMJ open, International Journal of Infectious Diseases**).
- Associate Editor for renowned international journals (**Infectious Diseases and Therapy, Frontiers Internal Medicine, Frontiers in Infectious Diseases**)
- Excellent knowledge of written and spoken English language

Personal Information

Address Via Edmondo De Amicis 9, 20123, Milan.

Telephone number +39 3401824285

E-mail marta.colaneri@unimi.it

Nationality Italian

Date of birth 01/02/1992

Gender Female

Current Position

Infectious Diseases specialist in Infectious Diseases Unit. Researcher at Department of Biomedical and Clinical Sciences , University Hospital "Luigi Sacco".
Assistant Professor at the Department of Biomedical and Clinical Sciences, University of Milan

Diagnosis, treatment and follow-up of infections in the critically-ill and immune compromised patients.

EDUCATION AND TRAINING

Tenure-Track Assistant Professor (RTT – Ricercatore a Tempo Determinato di Tipo B), Department of Clinical and Biomedical Science, University of Milan, Italy
Position leading to a tenured Associate Professorship upon successful evaluation

Type B Research Fellow (Assegnista di Ricerca di Tipo B)

Department of Clinical and Biomedical Science, University of Milan, Italy
Project: PNRR–INF–ACT – Strengthening the National Infrastructure for Pathogen

Type B Research Fellow (Assegnista di Ricerca di Tipo B)

Department of Infectious Diseases, University of Pavia, Italy
Project: PERISCOPE – Pan-European Response to the ImpactS of COVID-19 and future Pandemics and Epidemics

Jan 2018 - Dec 2021	<p>Infectious Diseases Specialty Training <i>Fondazione IRCCS Policlinico San Matteo” University Hospital – Università di Pavia, Viale Golgi Camillo 19 - 27100 Pavia (PV)</i> Mark: 70/70, <i>magna cum laude</i> Project title: ““Infection risk after transjugular intrahepatic portosystemic shunt: a retrospective observational study from a tertiary care centre in Northern Italy” Supervisor: Prof. Raffaele Bruno</p>
May 2020- Dec 2020	<p>Participation in the course "Fundamentals of Biomedical Statistics for Data Analysis," course hours: 24. The course was organized by Fondazione Ghislieri for members of the merit colleges "Collegio Ghislieri" and "Collegio Ca’ della Paglia." The instructor was Dr. Emanuele Giusti from IRCCS Istituto Auxologico Italiano, Pavia</p>
Jan 2021- May 2021	<p>Participation in the course "Research Methodology," course hours: 24. The course was organized by the "Fondazione Ghislieri" for members of the merit colleges "Collegio Ghislieri" and "Collegio Ca’ della Paglia." The Professor was Dr. Luigia Scudeller from IRCCS Azienda Ospedaliero-Universitaria di Bologna, Pavia.</p>
Academic year 2020-2021	<p>Participation in the seminars "A Coffee with the Grant Office," Topic: Project Management, Writing Research Projects for Competitive Grants, Research Methodology. Seminar hours: 18, organized by SSD Grant Office, Technology Transfer Office, and Scientific Documentation Service, IRCCS Policlinico San Matteo, Pavia (2020-2021).</p> <p>Participation in the seminars "Wednesday Clinical Grand Rounds," Topic: Discussion of Infectious Disease Clinical Cases, seminar hours: 18, organized by SSD Grant Office, Technology Transfer Office, and Scientific Documentation Service, IRCCS Policlinico San Matteo, Pavia (2020-2021).</p>
February 16 th , 2018	<p>Participation in the “Job Training in Infectious Diseases” organized by the Società Italiana di Malattie Infettive e Tropicali (SIMIT) <i>Unità di Malattie Infettive e Tropicali, Unità di Microbiologia Clinica e Unità di Farmacologia Clinica, Ospedale Luigi Sacco (2018-2019).</i></p>
July 27 th , 2016	<p>Master’s degree in medicine and surgery University of Milan, Milan, Italy Title of dissertation: ““Factors leading to success in treating hepatitis C virus with direct action therapy” Final score: 110/110, <i>magna cum laude</i></p>
July, 2016 – September, 2016	<p>Internship in Internal Medicine Unit of University Hospital Polydoro Ernani de São Thiago, Florianopolis, Brazil. Duration: 2 months</p>
August, 2015 – October, 2015	<p>Internship in Internal Medicine Unit and Infectious Diseases Unit of Mbale Regional Referral Hospital, Uganda. Duration: 3 months</p>
May, 2014 – July, 2014	<p>Internship in Infectious Diseases Unit of Prince Charles Hospital, Merthyr Tydfil, Cardiff, United Kingdom. Duration: 2 months</p>
July, 2012	<p>Classical High School Graduation <i>Liceo Classico Statale Alessandro Manzoni, Milan, Italy</i> Final score: 98/100</p>
CLINICAL ACTIVITY	
March 2020-March 2022	<p>Infectious Disease Specialist, contract for "Continuous Care Activity with a Co.Co.Co type contract." Activities include day, night, and holiday shifts, as well as clinical activities in the ward, outpatient clinic, and day hospital at the Unit of Infectious and Tropical Diseases, IRCCS Policlinico San Matteo di Pavia</p>
Jan 2018-Dec 2021	<p>Specialization in Infectious and Tropical Diseases, University of Pavia, Unit of Infectious and Tropical Diseases, IRCCS Policlinico San Matteo di Pavia</p>

Dec 2016-Dec 2017

Outpatient doctor for adults without housing resources, at Spazio Aperto Servizi SCS ONLUS, Casa dell'Accoglienza Enzo Jannacci, Milan

Academic year 2015-2016

Visiting student in the Unit of Infectious and Tropical Diseases, Luigi Sacco Hospital in Milan, total hours: 120. During the internship, I participated in clinical activities in the ward, outpatient clinic, and day hospital

SCIENTIFIC ACTIVITY

Clinical Research Activity

Jan 2023 - Present

Research collaboration contract, signed with Anlaids Onlus National Lombardy Section for clinical research activities at the Operating Unit of Infectious Diseases 2, Luigi Sacco Hospital in Milan.

Jan 2023 - Present

Research collaboration as a member of the "Centre for Multidisciplinary Research in Health Science (MACH)," University of Milan, for clinical research

Feb 2022-Sept 2022

Research grant at the University of Pavia as part of the project "Pan-European Response to the ImpactS of COVID-19 and future Pandemics and Epidemics (PERISCOPE)," funded through the HORIZON 2020 program, under the category "SOCIETAL CHALLENGES - Health, demographic change and well-being," topic: "SC1-PHE-CORONAVIRUS-2020-2C - Behavioural, social and economic impacts of the outbreak response," lead institution: University of Pavia

Scientific Publications

Scopus indexes on 04/04/2024:

H-index=21

Number of articles = 85 (26 as a first author)

Number of citations = 3,165

Editorial Activity

June, 2022 - Present

Member of the Editorial Board of "Frontiers in Virology" journal and of Infectious Diseases and Therapy

November, 2023 - Present

Associate Editor in the Editorial Board of "Frontiers in Clinical Microbiology" (section called 'Innovations in Infection Therapeutics).

Reviewer for international journals

Reviewer for renowned international journals (Scientific reports, BMJ open, International Journal of Infectious Diseases, Infection, Infectious diseases and Therapy, Respiratory Medicine).

Teaching activity

Academic Year: 2023-2024.

Lecturer for the lecture: "Control of the spread of multi-resistant bacteria at the local and global levels"

Within the Elective Course "Antibiotic Therapy and Drug Resistance" in the Degree Course in Medicine and Surgery – Central Campus, University of Milan.

Hours: 4

Academic Year: 2022-2023.

Lecturer for the lecture: "Antibiotic Resistance-AMR"

Within the "Master in Global Health - Second Level," course "Global Infectious Challenges," University of Milan.

Hours: 2

Academic Year: 2022-2023

Lecturer for the lecture: "Infectious Gastroenteritis and Foodborne Infections"

Within the Degree Course in Medicine and Surgery, Course "Infectious and Tropical Diseases," University of Milan.

Hours: 4

Academic Year: 2020-2021

Lecturer for the lecture series: "Empirical and targeted antibiotic therapy for multi-resistant germs"

Within the Specialization Course in Infectious and Tropical Diseases, University of Pavia. Course hours: 25

Academic Year: 2020-2021

Lecturer for the lecture: "Vaccinations and Variants of SARS-CoV-2: a model emphasizing the importance of non-pharmacological interventions in Italy for the control of COVID-19"

Within the Seminar: "Global and Italian Perspectives on COVID-19," Department of Public Health, University of Pavia.

Hours: 2

Mentoring Activities and Co-Supervisor for Medical Degree Theses

Academic Year: 2020-2021

Experimental Thesis, ID Number 44226:

Title: "Tenofovir Alafenamide Fumarate therapy in HIV-infected patients: impact on the metabolic profile and cardiovascular risk. A retrospective Study."

Supervisor: Prof. Raffaele Bruno, University of Pavia.

Experimental Thesis, ID Number 423563:

Title: "COVID-19 and Streptococcus Pneumoniae: results from the San Matteo COVID-19 Registry (SMACORE)."

Supervisor: Prof. Raffaele Bruno, University of Pavia.

Experimental Thesis, ID Number 422339:

Title: "Predictors of treatment in patients with non-tuberculous mycobacterial lung disease: a web-survey promoted by SITA GIOVANI – IRENE."

Supervisor: Prof. Raffaele Bruno, University of Pavia.

Participation in National research groups

Conception, Methodology Definition, and Coordination of Multicenter Observational Projects:

September, 2021 – Present

A multi-center quasi-experimental study in Northern Italy to evaluate the impact of Sepsis bundle in Obstetric Settings: the SOS study.

Role: Research Group Coordinator

Participating Centers: IRCCS Policlinico San Matteo di Pavia (lead center), Ospedale Buzzi di Milano, IRCCS Ca' Policlinico di Milano, Ca' Granda Niguarda di Milano, Ospedale di Cremona, Ospedale San Gerardo di Monza.

November, 2021 - Present

NAsal METHicillin-resistant Staphylococcus (NAMES) colonization study: the impact of antibiotic treatment on colonization and infection with methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children.

Role: Research Group Coordinator

Participating Centers: IRCCS Policlinico San Matteo di Pavia (lead center), Ospedale Buzzi di Milano, Ospedale Fatebenefratelli di Milano.

November, 2021 - Present

West Nile virus Encephalitis and Steroid Therapy: the WEST study: A multicentre study conducted in Northern Italy to evaluate the impact of steroid therapy in the West Nile virus encephalitis.

Role: Research Group Coordinator

Participating Centers: IRCCS Policlinico San Matteo di Pavia (lead center), Ospedale di Lodi, Ospedale di Cremona, Ospedale di Modena.

November, 2021 - Present

CONCEPT Study (Ceftazidime/Avibactam for Pseudomonas aeruginosa):

Role: Research Group Coordinator

Participating Centers: IRCCS Policlinico San Matteo di Pavia (lead center), Ospedale Luigi Sacco di Milano, IRCCS Policlinico di Milano, Ospedale Ca' Granda Niguarda di Milano, Ospedale di Siena, Ospedale di Lecco, Ospedale di Alessandria, Ospedale di Cremona, Ospedale San Gerardo di Monza.

March, 2021 - Present

A multidisciplinary approach to identify biomarkers of Post-Acute Sequelae of SARS-CoV-2 infection

Status: Recruiting.

Conception, Methodology Definition, and Coordination of Monocentric Observational Projects:

Academic year 2020-2022

I-Hospital Project (IT Platform for Nosocomial Infections Control):

Role: Research Group Coordinator. Location: IRCCS Policlinico San Matteo di Pavia.

TRIP Study (Timely Remdesivir for Immunocompromised Patients):

Role: Research Group Coordinator

Location: IRCCS Policlinico San Matteo di Pavia.

SURFACE Project (SARS-CoV-2 Surface Contamination):

Role: Research Group Coordinator.

Location: IRCCS Policlinico San Matteo di Pavia.

ReCeNSI Project (Local Registry of Central Nervous System Infections): Location:

IRCCS Policlinico San Matteo di Pavia.

SMACORE Project (Registry of COVID-19 Cases at IRCCS Policlinico San Matteo di Pavia): Location: IRCCS Policlinico San Matteo di Pavia.

**Participation in Research
Activities in the Following
National and International
Projects**

MULTI-SITA Study (Italian Society of Antimicrobial Therapy):

Organizer: Italian Society of Antimicrobial Therapy (SITA).

ECRAID Project (European Clinical Research Alliance on Infectious Diseases):

Coordinator: Marc Bonten, UMC Utrecht, Netherlands, and Evelina Tacconelli, University of Verona, Italy.

PROSAFE Project (Scientific Collaboration with Clinical Data Science Laboratory, Mario Negri Pharmacological Research Institute IRCCS): Location: GiViTI Coordination Center, Milan.

GEN-COVID Project (Impact of Host Genome on COVID-19 Clinical Variability):

Coordinator: University of Siena.

Modeling the Dynamics of the COVID-19 Epidemic, Spread of Variants, and Vaccination Rollouts:

Collaborative Group: Researchers from IRCCS Policlinico San Matteo, Politecnico di Milano, University of Trento, University of Udine, and University of Pavia.

Honours and awards

Travel Grants and awards

Nov 2024	“Sviluppo e valutazione di un nuovo score diagnostico per le candidiasi invasive nel Paziente critico ai fini della Antifungal Stewardship (SERENDIPITOUS)”, winner project for the Grant “Gilead Fellowship Program 2024”.
Dec 2024	“RSV vaccination longitudinal study in fragile patients”, winner project for the Grant “LINEA 2: Dotazione annuale per attività istituzionali”, DIBIC, UNIMI
Mar 2025	Winner for the Best Abstract at the II Edition of the TOP-5 in Infectious Diseases Conference, Venice 2025
Dec 2023	Research Award 2023," ANLAIDS Onlus - Lombardy Section: Description: Awarded as the best national researcher in the field of Infectious Diseases
Oct 4-7 2023	ECCMID Grant for ESCMID Postgraduate Educational Course: "Systematic reviews and meta-analyses for guidelines development in infectious diseases, infection control, and clinical microbiology"
June 7-9, 2022	ECCMID Grant for ESCMID Postgraduate Educational Course: "Last-line antibiotics against XDR/PDR Gram-negatives: Understanding phenotype-genotype correlations and PK/PD approaches": Location: Athens, Greece
July 29-Aug 2, 2022	Scholarship for Participation in the "24th International AIDS Conference": Supported by: Società Italiana Malattie Infettive e Tropicali (SIMIT), with the support of ViiV Healthcare. Location: Montreal, Canada
Academic year 2019-2020	Merit Scholarship awarded by "Fondazione Ghislieri" for Admission to "Collegio Ca' della Paglia"

Acceptance of oral presentations for international congresses:

Apr 2025	“The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization”, 35th European Congress of Clinical Microbiology and Infectious Diseases – ECCMID 2025.
Apr 2024	“A multicentre observational study in Northern Italy to evaluate the impact of sepsis bundle in obstetric settings: the SOS study”, 34th European Congress of Clinical Microbiology and Infectious Diseases – ECCMID 2024.
Dec 2023	“Early administration of Nirmatrelvir/Ritonavir Leads to Faster Negative SARS-CoV-2 Nasal Swabs Than Monoclonal Antibodies in COVID 19 Patients at High-Risk for Severe Disease”, XXII CONGRESSO NAZIONALE SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI (SIMIT),”
Oct 2023	Nuovi antibiotici: quale spazio in terapia empirica”, Attualità e Controversie in terapia antiinfettiva (ACTA REBOOT), organizzato da Prof. Paolo Bonfanti, Università di Milano-Bicocca, Prof. Andrea Gori Università degli Studi di Milano e Dr. Giuliano Rizzardini, Ospedale Luigi Sacco, Milano presso l'HILTON HOTEL, Milano
April 2023	“The west study: a multicentric study on the impact of steroid therapy in West Nile encephalitis”, Brief Oral Presentation, 33rd European Congress of Clinical Microbiology and Infectious Diseases – (ECCMID)
April 2021	“Mathematical models: anticipating Covid-19”, Giornata della Ricerca Webinar: "Come la ricerca sta rivoluzionando la cura" organizzato da Direttore Scientifico Giampaolo Merlini, presso Aula Magna “C. Golgi”, Policlinico IRCCS San Matteo of Pavia
Nov 2021	“The Impact of COVID-19 on HIV Care in our Tertiary Centre IRCCS Policlinico San Matteo of Pavia”, PERFORM 2021. Il Covid dopo il Covid: esperienze a confronto. Dopo la pandemia... cosa è cambiato per l'infettivologia lombarda? EVENTO FORMATIVO GIL. Organizzato da Prof.ssa Antonella D'Arminio Monforte, Professore ordinario di

Malattie Infettive presso Università degli Studi di Milano e Dott. Marco Rizzi, Direttore U.O.C. Malattie Infettive, ASST Papa Giovanni XXIII di Bergamo, Milano”

June 2020 “Running out of bullets: the challenging management of acute hepatitis and SARS-COV-2 from the SMatteo COvid19 Registry (SMACORE)”, organizzato da European Society of Clinical Microbiology and Infectious Diseases (ESCMID), ESCMID Conference on Coronavirus Disease (ECCVID), online

July 2020 “Covid-19 in Italy”, International Covid-19 Symposium, Sessione “Covid-19 and world experience”, organizzato da Prof. Mustafa Altindiş, Sakaria University, Turkey, online

Acceptance of abstracts for international congresses;

- “A worldwide survey on perioperative antimicrobial therapy for heart transplantation: from theory to clinical practice”, 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)”, Copenhagen, Denmark (2023).

- “The SURFACE study: what is the role of inanimate surfaces in the spread of SARS-CoV-2?”, 31th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)”, Copenhagen, Denmark (2023).

- “Ventilator-associated pneumonia due to MRSA vs MSSA: what should guide empiric therapy?”, 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)”, Lisbon, Portugal (2022).

- “Reduction of bloodstream infection associated mortality after introduction of a sepsis project in the emergency room of a tertiary referral hospital of northern Italy”, 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)”, Lisbon, Portugal (2022).

- “Monitoring and control of HAIs: validation of an IT platform on the data of a tertiary Centre in Northern Italy”, 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)”, Lisbon, Portugal (2022).

- “Impact of antibiotic resistance on the outcome of hospitalised patients: eight years' experience of a tertiary centre in northern Italy”, 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)”, Lisbon, Portugal (2022).

- “A radiologic score for pulmonary nontuberculous mycobacterial infection: preliminary results”, 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Online (2020).

- “All that glitters is not gold: a challenging case of dyspnea during the COVID-19 pandemic from the SMatteo COvid19 REgistry (SMACORE)”, Poster presso XIX CONGRESSO NAZIONALE SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI (SIMIT), Online (2020).

- “Otto anni di esperienza italiana sull'Infezione da Nocardia: quanto è importante l'immunosoppressione?”, Poster presso XVIII CONGRESSO NAZIONALE SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI (SIMIT), Palermo, Italy (2019).

- “Profilo farmacocinetico del dolutegravir dopo il posizionamento di shunt intraepatico portosistemico trans-giugulare”, Poster presso XVIII CONGRESSO NAZIONALE SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI (SIMIT), Palermo, Italy (2019).

- “Cryptococcosis in HIV-negative and HCV-positive patient on treatment with direct action antivirals (DAAs)”, Poster presso XVII CONGRESSO NAZIONALE SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI (SIMIT), Torino, Italy (2018).

Membership of Scientific Societies

European Society of Clinical Microbiology and Infectious Diseases

SIMIT Società Italiana di Malattie Infettive e Tropicali

SITA Società italiana di terapia antinfettiva antivirale antibatterica, antifungina

Languages

Mother language	Italian
Other languages	
English	C2 – Proficient User

Publications list: [https://pubmed.ncbi.nlm.nih.gov/?term=colaneri+M\[author\]](https://pubmed.ncbi.nlm.nih.gov/?term=colaneri+M[author])
List of scientific publications on international journals indexed on PubMed:

- 1.
2. Bandera A, **Colaneri M**, Galbusera AA, Canuti M, Dall'Olio L, Nobili A, Puoti M, Marchetti GC, Piva S, Plebani P, Raviglione M, Gori A, Cereda D, Leoni O, Fortino I, Ojeda Fernandez ML, Mannucci PM, Agosti P, Tediosi F, Baviera M, Tettamanti M. The impact of COVID-19 hospitalizations on nursing home admissions: a regional insight into long-term care and public health. *Front Public Health*. 2025 Jul 18;13:1613684. doi: 10.3389/fpubh.2025.1613684. PMID: 40756386; PMCID: PMC12315697
3. **Colaneri, M.**, Giordani, P., Milanesi, S. et al. From Colonisation to Infection: Assessing the BSI Potential in Patients with KPC, NDM, VRE and CRAB Rectal Colonisation. *Infect Dis Ther* (2025). <https://doi.org/10.1007/s40121-025-01222-2> Borgonovo F, **Colaneri M**, Fassio F, Scaglione G, Galli L, Offer M, Genovese C, Fattore R, Schiavini M, De Capitani G, Calloni M, Bartoli A, Casella F, Taino A, Gidaro A, Cogliati C, Breschi V, Leoni J, Gori A, Foschi A. The CONSIDER study: Assessing the risk of catheter-associated bloodstream infections beyond the intensive care setting. *Am J Infect Control*. 2025 Jun 6:S0196-6553(25)00407-9. doi: 10.1016/j.ajic.2025.05.020. Epub ahead of print. PMID: 40484027.
4. Lovaglio PG, Borgonovo F, Manzo Margiotta A, Mowafy M, **Colaneri M**, Bandera A, Gori A, Capetti AF. Estimating long COVID-19 prevalence across definitions and forms of sample selection. *Front Epidemiol*. 2025 May 30;5:1597799. doi: 10.3389/fepid.2025.1597799. PMID: 40520224; PMCID: PMC12164371.
5. **Colaneri M**, Montrucchio G, Scaglione G, Monti G, Tricella G, Genovese C, Agostini F, Dore F, Viaggi B, Brazzi L, Sanna V, Gori A, Palomba E, Offer M, Finazzi S. Incidence, microbiology, and mortality of ventilation-associated pneumonia in a large Italian cohort of critically ill patients: results from the PROSAFE project. *Clin Microbiol Infect*. 2025 May 27:S1198-743X(25)00257-5. doi: 10.1016/j.cmi.2025.05.026. Epub ahead of print. PMID: 40441355.
6. Schiuma M, **Colaneri M**, Cattaneo D, Fusi M, Civati A, Galimberti M, Cossu MV, Gervasoni C, Dolci A, Riva A, Antinori S, Gori A, Torre A. Rifampicin drug monitoring in TB patients: new evidence for increased dosage? *Int J Tuberc Lung Dis*. 2025 May 25;29(5):202-206. doi: 10.5588/ijtld.24.0465. PMID: 4028
7. Behring A, Mariani C, Gerbi M, Offer M, Matone M, Cattaneo D, Giacomelli A, **Colaneri M**, Giorgi R, Merli S, Piconi S, Antinori S, Gori A, Passerini M, Appropriateness of loading dose and TDM in patients treated with teicoplanin: a single-centre observational retrospective cohort study comparing single-daily and thrice-weekly regimens, *Journal of Antimicrobial Chemotherapy*, 2025;dkaf097
8. Scaglione G, Canuti M, Offer M, Breschi V, Piralla A, Baldanti F, Del Castillo G, Scovenna F, Buoro S, Morani F, Cereda D, Bandera A, Gori A, **and Colaneri M**. Burden and Outcomes of Severe Lower Respiratory Tract Infections with Unknown Etiology: A Retrospective Observational Study on Epidemiological Trends Over an 8-Year Period (2016-2024). *Infect Dis Ther*. 2025 Apr 10. doi: 10.1007/s40121-025-01148-9. Epub ahead of print. PMID: 40208411.

9. **Colaneri M**, Canuti M, Torrigiani G, Dall'Olio L, Bobbio C, Baldi SL, Nobili A, Puoti M, Marchetti G, Piva S, Plebani P, Raviglione M, Gori A, Cereda D, Leoni O, Fortino I, Ojeda-Fernandez ML, Baviera M, Tettamanti M, Bandera A. Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2. *Infect Dis Ther*. 2025 Jan 21. doi: 10.1007/s40121-024-01107-w. Epub ahead of print. PMID: 39838255.
10. **Colaneri M**, Galli L, Offer M, Borgonovo F, Scaglione G, Genovese C, Fattore R, Schiavini M, De Capitani G, Calloni M, Bartoli A, Gidaro A, Cogliati C, Antinori S, Gori A, Foschi A. Vascular Access Device Infections: Current Management Practices and the Role of Multidisciplinary Teams at a Large Hospital in Northern Italy. *Antibiotics (Basel)*. 2025 Jan 3;14(1):27. doi: 10.3390/antibiotics14010027. PMID: 39858313; PMCID: PMC11763287.
11. Scaglione G, **Colaneri M**, Offer M, Galli L, Borgonovo F, Genovese C, Fattore R, Schiavini M, Taino A, Calloni M, Casella F, Gidaro A, Fassio F, Breschi V, Leoni J, Cogliati C, Gori A, Foschi A. Epidemiology and Clinical Insights of Catheter-Related Candidemia in Non-ICU Patients with Vascular Access Devices. *Microorganisms*. 2024 Aug 6;12(8):1597. doi: 10.3390/microorganisms12081597. PMID: 39203438; PMCID: PMC11356456.
12. **Colaneri M**, Scaglione G, Fassio F, Galli L, Lai A, Bergna A, Gabrieli A, Tarkowski M, Ventura CD, Colombo V, Cordier L, Bernasconi D, Corbellino M, Dedivitiis G, Borghetti S, Visigalli D, Sollima S, Casalini G, Rizzardini G, Gori A, Antinori S, Riva A, Schiavini M. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease. *Virol J*. 2024 Mar 20;21(1):68. doi: 10.1186/s12985-024-02333-x. PMID: 38509536; PMCID: PMC10953281.
13. Canuti M, Fassio F, Genovese C, Giacomelli A, Ridolfo AL, Asperges E, Albi G, Bruno R, Antinori S, Muscatello A, Mariani B, Canetta C, Blasi F, Bandera A, Gori A & **Colaneri M**. Response to the Letter to the Editor Regarding “Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study”. *Infect Dis Ther* (2024). <https://doi.org/10.1007/s40121-024-01047-5>
14. Genovese C, **Colaneri M**, Pagano S, Schiuma M, Galli L, Fama F, Spinello A, Gori A, Torre A, Assessing the prevalence of schistosomiasis and strongyloidiasis in a tuberculosis clinic: the TB-TROPICare study, *Front. Trop. Dis*, 20 August 2024, Volume 5 - 2024 | <https://doi.org/10.3389/fitd.2024.1412871>
15. Casalini G, Pozza G, Giacomelli A, **Colaneri M**, Carrozzo G, Caloni B, Ciubotariu CL, Zacheo M, Rabbione A, Pieruzzi M, Barone F, Passerini M, Ridolfo AL, Rizzardini G, Gori A, Antinori S. Major Bleeding Events in Hospitalized COVID-19 Patients: A Retrospective Observational Study. *Medicina (Kaunas)*. 2024 May 15;60(5):814. doi: 10.3390/medicina60050814. PMID: 38792997; PMCID: PMC11122796.
16. Pozza G, Mariani C, Passerini M, **Colaneri M**, Giacomelli A, Prokop L.J, Mohammad H. Murad M.H, Schiavini M, Gori A, Antinori S, Prevalence of extracardiac vascular complications in *Abiotrophia* spp. and *Granulicatella* spp. infective endocarditis: Two case reports and a systematic review, *Clinical Infection in Practice*, Volume 23, 2024, 100367, ISSN 2590-1702, <https://doi.org/10.1016/j.clinpr.2024.100367>.

17. Giacomelli A, Ciobotariu CL, Zacheo M, Rabbione A, Pieruzzi M, Barone F, Poloni A, Casalini G, Pozza G, **Colaneri M**, Passerini M, Ridolfo AL, Gervasoni C, Cattaneo D, Gori A, Antinori S. Mismanagement of SARS-CoV-2 Infection Pre-Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals. *Viruses*. 2024 Jun 22;16(7):1005. doi: 10.3390/v16071005. PMID: 39066168; PMCID: PMC11281468. Teicoplan
18. Scaglione G, **Colaneri M**, Offer M, Galli L, Borgonovo F, Genovese C, Fattore R, Schiavini M, Taino A, Calloni M, Casella F, Gidaro A, Fassio F, Breschi V, Leoni J, Cogliati C, Gori A, Foschi A. Epidemiology and Clinical Insights of Catheter-Related Candidemia in Non-ICU Patients with Vascular Access Devices. *Microorganisms*. 2024 Aug 6;12(8):1597. doi: 10.3390/microorganisms12081597. PMID: 39203438; PMCID: PMC11356456.
19. Lombardi A, **Colaneri M**, Azzarà C, Saltini P, Viero G, Palomba E, Biscarini S, Gori A, Bandera A. Solid organ transplant in recipients with ongoing SARS-CoV-2 infection: A systematic review of case reports and series. *Int J Infect Dis*. 2024 Aug 22;147:107214. doi: 10.1016/j.ijid.2024.107214. Epub ahead of print. PMID: 39179150. Letter-score npl
20. Scaglione G, Perego M, **Colaneri M***, Genovese C, Brivio F, Covizzi A, Viaggi B, Bandera A, Gori A, Finazzi S, Palomba E, Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units”, *Frontiers in Microbiology-Antimicrobials, Resistance and Chemotherapy*, *Front. Microbiol*, 2024 June; 15:1405390, doi:10.3389/fmicb.2024.1405390
21. **Colaneri M**, Genovese C, Valsecchi P, Calia M, Cattaneo D, Gori A, Bruno R, Seminari E. Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges. *Eur J Drug Metab Pharmacokinet*. 2024 Mar;49(2):123-129. doi: 10.1007/s13318-024-00882-8. Epub 2024 Feb 8. PMID: 38332425.
22. **Colaneri M**, Genovese C, Lombardi A, Holmes D, Bandera A, Gori A. Carbapenem or new β -lactam- β -lactamase inhibitors? An Italian survey supported by SITA, SIMIT and SIAARTI to identify the factors affecting empiric antimicrobial therapy choice in real-life clinical practice. *Eur J Clin Microbiol Infect Dis*. 2024 Mar 8. doi: 10.1007/s10096-024-04798-8. Epub ahead of print. PMID: 38457097.
23. **Colaneri M**, Scaglione G, Fassio F, Galli L, Lai A, Bergna A, Gabrieli A, Tarkowski M, Ventura CD, Colombo V, Cordier L, Bernasconi D, Corbellino M, Dedivitiis G, Borghetti S, Visigalli D, Sollima S, Casalini G, Rizzardini G, Gori A, Antinori S, Riva A, Schiavini M. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease. *Viol J*. 2024 Mar 20;21(1):68. doi: 10.1186/s12985-024-02333-x. PMID: 38509536; PMCID: PMC10953281.
24. **Colaneri M**, Genovese C, Fassio F, Canuti M, Giacomelli A, Ridolfo AL, Asperges E, Albi G, Bruno R, Antinori S, Muscatello A, Mariani B, Canetta C, Blasi F, Bandera A, Gori A. Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study. *Infect Dis Ther*. 2024 Apr 21. doi: 10.1007/s40121-024-00967-6. Epub ahead of print. PMID: 38643431.
25. Lombardi A, Villa S, **Colaneri M**, Scaglione G, Bai F, Varisco B, Bono V, Vena A, Dentone C, Russo C, Tettamanti M, Renisi G, Viero G, Azzarà C, Mantero M, Peyvandi F, Bassetti M,

- Marchetti G, Muscatello A, Nobili A, Gori A, Bandera A, and COVID-19 NETWORK, Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy- Article accepted for publication in *Journal of Infection and Public Health* on 31 Dec 2023 (Article reference JIPH23)
26. Palomba E, **Colaneri M**, Azzarà C, Fava M, Maccaro A, Renisi G, Viero G, Kaur H, Chakrabarti A, Gori A, Lombardi A, Bandera A, *Epidemiology, clinical manifestations, and outcome of mucormycosis in solid organ transplant recipients: a systematic review of reported cases*, *Open Forum Infectious Diseases*, 2024;, ofae043, <https://doi.org/10.1093/ofid/ofae043> 45).
 27. Cattaneo D, Fusi M, **Colaneri M**, Fusetti C, Genovese C, Giorgi R, Matone M, Merli S, Petri F, Gori A. Therapeutic drug monitoring of dalbavancin in real-life: a 2-year experience. Article accepted for publication in on 22 Dec 2023 (Article reference: antibiotics-2752326).
 28. Cattaneo D, Fusi M, Galli L, Genovese C, Giorgi R, Matone M, Merli S, **Colaneri M**, Gori A. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections. *Antimicrob Agents Chemother*. 2024 Apr 3;68(4):e0002324. doi: 10.1128/aac.00023-24. Epub 2024 Feb 22. PMID: 38385700; PMCID: PMC10989011.
 29. Holmes D, **Colaneri M**, Palomba E, and Gori A, Exploring post-SEPSIS and post-COVID-19 syndromes crossovers: from pathophysiology to therapeutic approach. Article accepted for publication in *Front. Med.* (Article reference: 10:1280951. doi: 10.3389/fmed.2023.1280951).
 30. Vecchia M, **Colaneri M**, Sacchi P, Marvulli LN, Salvaderi A, Lanza J, Boschini S, Ragni F, Marone P, Cutti S, Muzzi A,arena C, Calvi M, et al. Implementation of an antimicrobial stewardship program in the Vascular Surgery ward of a university tertiary care hospital in Pavia, Northern Italy. *BMC Infectious Diseases*. 2023;23(1). doi:10.1186/s12879-023-08061-x. Numero citazioni (Scopus) = 3.
 31. Seminari E, Ladini GS, **Colaneri M**, Chow J, Bruno R. A worldwide survey on perioperative antimicrobial prophylaxis for heart transplantation: From theory to clinical practice. *Transplant Infectious Disease*. 2023;25(2). doi:10.1111/tid.14034. Numero citazioni (Scopus) = 0.
 32. Seminari E, **Colaneri M**, Corbella M, De Silvestri A, Muzzi A, Perlini S, Martino IF, Marvulli LN, Arcuri A, Maffezzoni M, Minucci R, Bono E, Cambieri P, et al. Reduction of BSI associated mortality after a sepsis project implementation in the ER of a tertiary referral hospital. *Scientific Reports*. 2023;13(1). doi:10.1038/s41598-023-31219-1. Numero citazioni (Scopus) = 0.
 33. Seminari E, Cambieri P, Pieri TC, Roda S, **Colaneri M**, Gallazzi I, Asperges E, Bono E, Lissandrin R, Marvulli LN, Bruno R. Culture negative endocarditis and the role of proper blood culture collection: results from a tertiary care Centre of Northern Italy. *Infectious Diseases*. 2023;55(1):67-70. doi:10.1080/23744235.2022.2121854. Numero citazioni (Scopus) = 0.
 34. Sammartino JC, **Colaneri M**, Bassoli C, Ceresini M, Piralla A, Ferrari A, Percivalle E, Baldanti F, Bruno R, Mondelli MU. Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study. *Journal of Infection and Public Health*. 2023;16(5):736-740. doi:10.1016/j.jiph.2023.03.016. Numero citazioni (Scopus) = 2.

35. Milanese S, Rosset F, **Colaneri M**, Giordano G, Pesenti K, Blanchini F, Bolzern P, Colaneri P, Sacchi P, De Nicolao G, Bruno R. Early detection of variants of concern via funnel plots of regional reproduction numbers. *Scientific Reports*. 2023;13(1). doi:10.1038/s41598-022-27116-8. Numero citazioni (Scopus) = 1.
36. **Colaneri M**, Lissandrin R, Calia M, Bassoli C, Seminari E, Pavesi A, Rovida F, Baldanti F, Muzzi A, Chichino G, Regazzetti A, Grecchi C, Pan A, et al. The WEST Study: A Retrospective and Multicentric Study on the Impact of Steroid Therapy in West Nile Encephalitis. *Open Forum Infectious Diseases*. 2023;10(3). doi:10.1093/ofid/ofad092. Numero citazioni (Scopus) = 0.
37. **Colaneri M**, Giusti EM, Genovese C, Galli L, Lombardi A, Gori A. Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis. *Open Forum Infectious Diseases*. 2023;10(7). doi:10.1093/ofid/ofad358. Numero citazioni (Scopus) = 1.
38. Bergantini L, Baldassarri M, d'Alessandro M, Brunelli G, Fabbri G, Zguro K, Degl'Innocenti A, Mari F, Daga S, Meloni I, Bruttini M, Croci S, Lista M, et al. Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder. *Respiratory Research*. 2023;24(1). doi:10.1186/s12931-023-02458-7. Numero citazioni (Scopus) = 2.
39. Bergamaschi G, Barteselli C, Del Rio V, Borrelli de Andreis F, Pellegrino I, Mengoli C, Miceli E, Colaneri M, Zuccaro V, Di Stefano M, Bruno R, Di Sabatino A, Abruzzese GM, et al. Impaired respiratory function reduces haemoglobin oxygen affinity in COVID-19. *British Journal of Haematology*. 2023;200(5):e44-e47. doi:10.1111/bjh.18620. . Numero citazioni (Scopus) = 2.
40. Asperges E, Albi G, Zuccaro V, Sambo M, Pieri TC, Calia M, **Colaneri M**, Maiocchi L, Melazzini F, Lasagna A, Peri A, Mojoli F, Sacchi P, et al. Dynamic NLR and PLR in Predicting COVID-19 Severity: A Retrospective Cohort Study. *Infectious Diseases and Therapy*. 2023;12(6):1625-1640. doi:10.1007/s40121-023-00813-1. Numero citazioni (Scopus) = 1.
41. Zuccaro V, **Colaneri M**, Asperges E, Valsecchi P, Sambo M, Maiocchi L, Sacchi P, Muzzi A, Musella V, Cutti S, Rettani M, Mojoli F, Perlini S, et al. Mortality due to COVID-19 during the pandemic: A comparison of first, secondo and third SMAtteo COvid19 REgistry (SMACORE). *Heliyon*. 2022;8(2). doi:10.1016/j.heliyon.2022.e08895. Numero citazioni (Scopus) = 1.
42. Rossetti B, Borgo V, Emiliozzi A, **Colaneri M**, Zanelli G, D'alessandro M, Motta D, Maiocchi L, Montagnani F, Moioli MC, Baiguera C, Sambo M, Pieri TC, et al. Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection. *Diagnostics*. 2022;12(1). doi:10.3390/diagnostics12010014. Numero citazioni (Scopus) = 2.
43. Ricciardi A, Zelini P, Cassaniti I, Avanzini MA, **Colaneri M**, De Silvestri A, Baldanti F, Bruno R. Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children. *International Journal of Infectious Diseases*. 2022;122:905-909. doi:10.1016/j.ijid.2022.06.055. Numero citazioni (Scopus) = 8.
44. Onoja A, Picchiotti N, Fallerini C, Baldassarri M, Fava F, Mari F, Daga S, Benetti E, Bruttini M, Palmieri M, Croci S, Amitrano S, Meloni I, et al. An explainable model of host genetic interactions linked to COVID-19 severity. *Communications Biology*. 2022;5(1). doi:10.1038/s42003-022-04073-6. Numero citazioni (Scopus) = 2.

45. Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, Kumagai-Braesh M, Andréll J, Percivalle E, Sammartino JC, Wang Y, Vlachiots S, Attevall J, et al. Immunity to SARS-CoV-2 up to 15 months after infection. *iScience*. 2022;25(2). doi:10.1016/j.isci.2022.103743. Numero citazioni (Scopus) = 48.
46. Mantovani S, Daga S, Fallerini C, Baldassarri M, Benetti E, Picchiotti N, Fava F, Galli A, Zibellini S, Bruttini M, Palmieri M, Croci S, Amitrano S, et al. Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. *Genes and Immunity*. 2022;23(1):51-56. doi:10.1038/s41435-021-00157-1. Numero citazioni (Scopus) = 25.
47. Fallerini C, Picchiotti N, Baldassarri M, Zguro K, Daga S, Fava F, Benetti E, Amitrano S, Bruttini M, Palmieri M, Croci S, Lista M, Beligni G, et al. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. *Human Genetics*. 2022;141(1):147-173. doi:10.1007/s00439-021-02397-7. Numero citazioni (Scopus) = 18.
48. **Colaneri M**, Valsecchi P, Vancheri SG, Valentini A, Marchetti F, Tarantino F, Sambo M, Fabbiani M, Calliada F, Monzillo V, Di Matteo A, Maiocchi L, Lombardi A, et al. Is a radiological score needed to define the severity of Nontuberculous mycobacteria lung disease? *New Microbiologica*. 2022;45(4):237-242. Numero citazioni (Scopus) = 0.
49. **Colaneri M**, Pieri TC, Roda S, Ricciardi A, Gotti M, Ferrari J, Arcaini L, Rattotti S, Piralla A, Giardina F, Ferrari G, Sacchi P, Zuccaro V, et al. Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy. *Journal of Clinical Medicine*. 2022;11(24). doi:10.3390/jcm11247452. Numero citazioni (Scopus) = 1.
50. **Colaneri M**, Lombardi A, Maffezzoni M, Sambo M, Fabbiani M, Quaretti P, Asperges E, Moramarco L, Sacchi P, Bruno R. The infection risk after transjugular intrahepatic portosystemic shunt: A multiple competing risk analysis from a tertiary care center. *Digestive and Liver Disease*. 2022;54(12):1686-1690. doi:10.1016/j.dld.2022.05.005. Numero citazioni (Scopus) = 0.
51. **Colaneri M**, Di Carlo D, Amatu A, Marvulli LN, Corbella M, Petazzoni G, Cambieri P, Muzzi A, Bandi C, Di Matteo A, Sacchi P, Mojoli F, Bruno R. Ventilator-Associated Pneumonia Due to MRSA vs. MSSA: What Should Guide Empiric Therapy? *Antibiotics*. 2022;11(7). doi:10.3390/antibiotics11070851. Numero citazioni (Scopus) = 1.
52. **Colaneri M**, Di Benedetto A, Marvulli LN, Bocchio F, Cutti S, Marena C, Calvi M, Bruno R. Are people previously infected with SARS-CoV-2 likely to experience COVID-19 symptoms again after vaccination? Results from an Italian COVID-19 referral center. *Human Vaccines and Immunotherapeutics*. 2022;18(1). doi:10.1080/21645515.2021.1920273. Numero citazioni (Scopus) = 1
53. **Colaneri M**, Asperges E, Calia M, Sacchi P, Rettani M, Cutti S, Albi G, Bruno R. Despite Vaccination: A Real-Life Experience of Severe and Life-Threatening COVID-19 in Vaccinated and Unvaccinated Patients. *Vaccines*. 2022;10(9). doi:10.3390/vaccines10091540. Numero citazioni (Scopus) = 0.

54. **Colaneri M**, Amarasinghe N, Rezzonico L, Pieri TC, Segalini E, Sambo M, Roda S, Meloni F, Gregorini M, Rampino T, Pelenghi S, Ricciardi A, Bruno R. Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy. *International Journal of Infectious Diseases*. 2022;121:157-160. doi:10.1016/j.ijid.2022.05.001. Numero citazioni (Scopus) = 10.
55. Zuccaro V, Celsa C, Sambo M, Battaglia S, Sacchi P, Biscarini S, Valsecchi P, Pieri TC, Gallazzi I, **Colaneri M**, Sachs M, Roda S, Asperges E, et al. Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAAtteo COvid19 REgistry (SMACORE). *Scientific Reports*. 2021;11(1). doi:10.1038/s41598-020-80679-2. Numero citazioni (Scopus) = 18.
56. Zuccaro V, Asperges E, **Colaneri M**, Marvulli LN, Bruno R. Hbv and hdv: New treatments on the horizon. *Journal of Clinical Medicine*. 2021;10(18). doi:10.3390/jcm10184054. Numero citazioni (Scopus) = 3.
57. Valsecchi P, **Colaneri M**, Zuccaro V, Asperges E, Costanzo F, Mariani B, Roda S, Minucci R, Bertuccio F, Fraoilini E, Bosio M, Tirelli C, Oggioni T, et al. Impact of pneumococcal urinary antigen testing in covid-19 patients: Outcomes from the san matteo covid-19 registry (smacore). *Journal of Personalized Medicine*. 2021;11(8). doi:10.3390/jpm11080762. Numero citazioni (Scopus) = 2.
58. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, Braesch-Andersen S, Cassaniti I, Percivalle E, Sarasini A, Bergami F, Di Martino R, Colaneri M, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. *Med*. 2021;2(3):281-295.e4. doi:10.1016/j.medj.2021.02.001. Numero citazioni (Scopus) = 134.
59. Paolucci S, Cassaniti I, Novazzi F, Fiorina L, Piralla A, Comolli G, Bruno R, Maserati R, Gulminetti R, Novati S, Mojoli F, Baldanti F, Mondelli M, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. *International Journal of Infectious Diseases*. 2021;104:315-319. doi:10.1016/j.ijid.2020.12.051. Numero citazioni (Scopus) = 55.
60. Mondelli MU, **Colaneri M**, Seminari EM, Baldanti F, Bruno R. Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. *The Lancet Infectious Diseases*. 2021;21(5):e112. doi:10.1016/S1473-3099(20)30678-2. Numero citazioni (Scopus) = 108.
61. Melazzini F, Colaneri M, Fumoso F, Freddi G, Lenti MV, Pieri TC, Piloni D, Noris P, Pieresca C, Preti PS, Russo M, Corsico A, Tavazzi G, et al. Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. *Internal and Emergency Medicine*. 2021;16(5):1141-1152. doi:10.1007/s11739-020-02550-6. Numero citazioni (Scopus) = 8.
62. Lombardi A, **Colaneri M**, Vijayagopal KA, Sambo M, Legnazzi P, Sacchi P, Zuccaro V, Maiocchi L, Maserati R, Gulminetti R, Pagnucco L, Novati S, Zanaboni D, et al. Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing? *Digestive and Liver Disease*. 2021;53(4):456-460. doi:10.1016/j.dld.2020.07.013. Numero citazioni (Scopus) = 0.

63. Lombardi A, **Colaneri M**, Sambo M, Di Matteo A, Sacchi P, Fabbiani M, Codecasa L, Aliberti S, Blasi F, Bandera A, Bruno R, Gori A. Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. *Respiratory Medicine*. 2021;179. doi:10.1016/j.rmed.2021.106341. Numero citazioni (Scopus) =2.
64. Giordano G, **Colaneri M**, Di Filippo A, Blanchini F, Bolzern P, De Nicolao G, Sacchi P, Colaneri P, Bruno R. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. *Nature Medicine*. 2021;27(6):993-998. doi:10.1038/s41591-021-01334-5. Numero citazioni (Scopus) = 131.
65. Fabbiani M, Lombardi A, **Colaneri M**, Del Poggio P, Perini P, D'Ambrosio R, Degasperis E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, et al. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. *Journal of Viral Hepatitis*. 2021;28(3):558-568. doi:10.1111/jvh.13454. Numero citazioni (Scopus) = 2.
66. De Gregori S, De Silvestri A, Molinaro MD, Monzillo V, Biscarini S, **Colaneri M**, Gallazzi I, Bartoli A, Bruno R, Seminari E. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. *European Journal of Drug Metabolism and Pharmacokinetics*. 2021;46(4):547-554. doi:10.1007/s13318-021-00690-4. Numero citazioni (Scopus) = 0.
67. **Colaneri M**, Valsecchi P, Vecchia M, Di Filippo A, Zuccaro V, Seminari E, Sacchi P, Maiocchi L, Fabbiani M, Ricciardi A, Muzzi A, Bruno R. What prompts clinicians to start antibiotic treatment in COVID-19 patients? An Italian web survey helps us to understand where the doubts lie. *Journal of Global Antimicrobial Resistance*. 2021;26:74-76. doi:10.1016/j.jgar.2021.05.014. Numero citazioni (Scopus) = 3.
68. **Colaneri M**, Novelli V, Cutti S, Muzzi A, Resani G, Monti MC, Rona C, Grugnetti AM, Rettani M, Rovida F, Zuccaro V, Triarico A, Marena C. The experience of the health care workers of a severely hit SARS-CoV-2 referral Hospital in Italy: incidence, clinical course and modifiable risk factors for COVID-19 infection. *Journal of Public Health (United Kingdom)*. 2021;43(1):26-34. doi:10.1093/pubmed/fdaa195. Numero citazioni (Scopus) = 22.
69. **Colaneri M**, Lupi M, Sachs M, Ludovisi S, Matteo AD, Pagnucco L, Gulminetti R, Mariani B, Fabbiani M, Bruno R. A challenging case of SARS-CoV-2- AIDS and Nocardiosis coinfection from the SMatteo COVID-19 Registry (SMACORE). *New Microbiologica*. 2021;44(2):129-134. Numero citazioni (Scopus) = 3.
70. Colaneri M, Lombardi A, Morea A, Monzillo V, Mariani B, Marone P, Sciarra M, Sambo M, Brunetti E, Bruno R, Seminari E. An eight-year experience of Nocardia infection in Italy: Does immunosuppression matter? *New Microbiologica*. 2021;44(2):111-116. Numero citazioni (Scopus) = 2.
71. **Colaneri M**, De Filippo M, Licari A, Marseglia A, Maiocchi L, Ricciardi A, Corsico A, Marseglia G, Mondelli MU, Bruno R. COVID vaccination and asthma exacerbation: might there be a link? *International Journal of Infectious Diseases*. 2021;112:243-246. doi:10.1016/j.ijid.2021.09.026. Numero citazioni (Scopus) = 15.


72. Cassaniti I, Percivalle E, Bergami F, Piralla A, Comolli G, Bruno R, Vecchia M, Sambo M, Colaneri M, Zuccaro V, Benazzo M, Robotti C, Calastri A, et al. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. *Clinical Microbiology and Infection*. 2021;27(7):1029-1034. doi:10.1016/j.cmi.2021.03.010. Numero citazioni (Scopus) = 45.
73. Biscarini S, **Colaneri M**, Mariani B, Pieri TC, Bruno R, Seminari E. A case of *Corynebacterium striatum* endocarditis successfully treated with an early switch to oral antimicrobial therapy. *Infezioni in Medicina*. 2021;29(1):138-144. Numero citazioni (Scopus) = 4.
74. Seminari E, **Colaneri M**, Sambo M, Gallazzi I, Di Matteo A, Roda S, Bruno R, Mondelli MU, Brunetti E, Maiocchi L, Zuccaro V, Pagnucco L, Mariani B, et al. SARS Cov-2 infection in a renal-transplanted patient: A case report. *American Journal of Transplantation*. 2020;20(7):1882-1884. doi:10.1111/ajt.15902. Numero citazioni (Scopus) = 73.
75. Rovida F, Cereda D, Novati S, Licari A, Triarico A, Marseglia GL, Bruno R, Baldanti F, Mondelli M, Brunetti E, Di Matteo A, Seminari E, Maiocchi L, et al. Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. *Clinical Microbiology and Infection*. 2020;26(11):1569-1571. doi:10.1016/j.cmi.2020.06.006. Numero citazioni (Scopus) = 5.
76. Perlini S, Canevari F, Cortesi S, Sgromo V, Brancaglione A, Contri E, Pettenazza P, Salinaro F, Speciale F, Sechi G, Mare C, Cutti S, Novelli V, et al. Emergency Department and Out-of-Hospital Emergency System (112—AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. *Internal and Emergency Medicine*. 2020;15(5):825-833. doi:10.1007/s11739-020-02390-4. Numero citazioni (Scopus) = 46.
77. Novazzi F, Cassaniti I, Piralla A, Di Sabatino A, Bruno R, Baldanti F, Mondelli M, Brunetti E, Di Matteo A, Seminari E, Maiocchi L, Zuccaro V, Pagnucco L, et al. Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. *Pediatric Allergy and Immunology*. 2020;31(S26):72-74. doi:10.1111/pai.13366. Numero citazioni (Scopus) = 4.
78. Magrassi L, Mussa M, Montalbetti A, **Colaneri M**, di Matteo A, Malfitano A, Simoncelli AM, Egitto MG, Bernucci C, Brunetti E. Primary Spinal Epidural Abscesses Not Associated With Pyogenic Infectious Spondylodiscitis: A New Pathogenetic Hypothesis. *Frontiers in Surgery*. 2020;7. doi:10.3389/fsurg.2020.00020. Numero citazioni (Scopus) = 9.
79. Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, **Colaneri M**. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. *Nature Medicine*. 2020;26(6):855-860. doi:10.1038/s41591-020-0883-7. Numero citazioni (Scopus) = 1161.
80. Fabbiani M, Cattaneo D, Lombardi A, Colaneri M, Sambo M, Novati S, Fusi M, Bruno R. Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. *Journal of Antimicrobial Chemotherapy*. 2020;75(5):1354-1356. doi:10.1093/jac/dkz572. Numero citazioni (Scopus) = 1.

81. **Colaneri M**, Valsecchi P, Perotti L, Ludovisi S, Seminari E, Pieri TC, Sacchi P, Bruno R. Running out of bullets: The challenging management of acute hepatitis and SARS-COV-2 from the SMatteo COvid19 Registry (SMACORE). *Liver International*. 2020;40(11):2655-2659. doi:10.1111/liv.14609. Numero citazioni (Scopus) = 6.
82. **Colaneri M**, Seminari E, Piralla A, Zuccaro V, Di Filippo A, Baldanti F, Bruno R, Mondelli MU, Brunetti E, Di Matteo A, Maiocchi L, Pagnucco L, Mariani B, et al. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. *Journal of Hospital Infection*. 2020;105(3):474-476. doi:10.1016/j.jhin.2020.03.018. Numero citazioni (Scopus) = 51.
83. **Colaneri M**, Seminari E, Novati S, Asperges E, Biscarini S, Piralla A, Percivalle E, Cassaniti I, Baldanti F, Bruno R, Mondelli MU, Brunetti E, Di Matteo A, et al. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. *Clinical Microbiology and Infection*. 2020;26(8):1094.e1-1094.e5. doi:10.1016/j.cmi.2020.05.009. Numero citazioni (Scopus) = 107.
84. **Colaneri M**, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, Pieri TC, Valsecchi P, Piralla A, Seminari E, Matteo AD, Novati S, Maiocchi L, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. *Eurosurveillance*. 2020;25(16). doi:10.2807/1560-7917.ES.2020.25.16.2000460. Numero citazioni (Scopus) = 89.
85. **Colaneri M**, Cavanna C, Mussa M, Morea A, Manciuilli T, Brunetti E, Matteo AD, Lallitto F. Cryptococcosis in an HIV-negative, HCV positive, immunosenescent patient: A case report. *New Microbiologica*. 2020;43(2):99-102. Numero citazioni (Scopus) = 0.
86. **Colaneri M**, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, Montecucco C, Mojoli F, Giusti EM, Bruno R, Mondelli MU, Brunetti E, Di Matteo A, et al. Tocilizumab for treatment of severe covid-19 patients: Preliminary results from smatteo covid19 registry (smacore). *Microorganisms*. 2020;8(5). doi:10.3390/microorganisms8050695. Numero citazioni (Scopus) = 162.
87. Bruno R, Mondelli M, Brunetti E, Matteo AD, Seminari E, Maiocchi L, Zuccaro V, Pagnucco L, Mariani B, Ludovisi S, Lissandrin R, Parisi A, Sacchi P, et al. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. *Journal of Medical Virology*. 2020;92(10):1724-1727. doi:10.1002/jmv.25800. Numero citazioni (Scopus) = 180.
88. Biscarini S, **Colaneri M**, Ludovisi S, Seminari E, Pieri TC, Valsecchi P, Gallazzi I, Giusti E, Cammà C, Zuccaro V, Mondelli MU. The obesity paradox: Analysis from the SMatteo COvid-19 REgistry (SMACORE) cohort. *Nutrition, Metabolism and Cardiovascular Diseases*. 2020;30(11):1920-1925. doi:10.1016/j.numecd.2020.07.047. Numero citazioni (Scopus) = 44
89. Asperges E, Novati S, Muzzi A, Biscarini S, Sciarra M, Lupi M, Sambo M, Gallazzi I, Peverini M, Lago P, Mojoli F, Perlini S, Bruno R, et al. Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. *Journal*

of Hospital Infection. 2020;105(3):477-479. doi:10.1016/j.jhin.2020.03.020. Numero citazioni (Scopus) = 25.

I hereby authorize the use of my personal data in accordance to the GDPR 679/16 - "European regulation on the protection of personal data".

Il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 D. Lgs. 30 giugno 2003 n. 196 – "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali".

A handwritten signature in black ink that reads "Marta Colaneri". The signature is written in a cursive style.

1478 Dr.ssa COLANERI MARTA
CLN MRT 92B41 F205V
Malattie Infettive I
FONDAZIONE IRCCS POLICLINICO S. MATTEO - PV